Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program Funds to be used to demonstrate efficacy in a new mouse model of cutaneous lupus GREENVILLE, SC, May 31, 2023 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod® topical delivery...

Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra GREENVILLE, SC, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...

Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus) Funds to be used to optimize a formulation and prepare for scale-up and IND-enabling studies GREENVILLE, SC, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...